Transplant International最新文献_第10页

IF 2.7 3区医学

Transplant International Pub Date : 2024-12-11 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.14105

Simon R Knight

引用次数: 0

Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study. Belatacept抢救转化后活检证实的t细胞介导的排斥反应：一项多中心回顾性研究。

IF 2.7 3区医学

Transplant International Pub Date : 2024-12-06 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13544

Dominique Bertrand, Nathalie Chavarot, Jérôme Olagne, Clarisse Greze, Philippe Gatault, Clément Danthu, Charlotte Colosio, Maïté Jaureguy, Agnès Duveau, Nicolas Bouvier, Yannick Le Meur, Léonard Golbin, Eric Thervet, Antoine Thierry, Arnaud François, Charlotte Laurent, Mathilde Lemoine, Dany Anglicheau, Dominique Guerrot

{"title":"Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study.","authors":"Dominique Bertrand, Nathalie Chavarot, Jérôme Olagne, Clarisse Greze, Philippe Gatault, Clément Danthu, Charlotte Colosio, Maïté Jaureguy, Agnès Duveau, Nicolas Bouvier, Yannick Le Meur, Léonard Golbin, Eric Thervet, Antoine Thierry, Arnaud François, Charlotte Laurent, Mathilde Lemoine, Dany Anglicheau, Dominique Guerrot","doi":"10.3389/ti.2024.13544","DOIUrl":"10.3389/ti.2024.13544","url":null,"abstract":"After kidney transplantation, conversion to belatacept is a promising alternative in patients with poor graft function or intolerance to calcineurin inhibitors. The risk of acute rejection has not been well described under these conditions. Here we present a retrospective multicenter study investigating the occurrence of acute rejection after conversion in 901 patients (2011-2021). The incidence of cellular and humoral rejection was 5.2% and 0.9%, respectively. T-cell mediated rejection (TCMR) occurred after a median of 2.6 months after conversion. Out of 47 patients with TCMR, death-censored graft survival was 70.1%, 55.1% and 50.8% at 1 year, 3 years and 5 years post-rejection, respectively. Eight patients died after rejection, mainly from infectious diseases. We compared these 47 patients with a cohort of kidney transplant recipients who were converted to belatacept between 2011 and 2017 and did not develop rejection (n = 238). In multivariate analysis, shorter time between KT and conversion, and the absence of anti-thymocyte globulin induction after KT were associated with the occurrence of TCMR after belatacept conversion. The occurrence of rejection after conversion to belatacept appeared to be less frequent than with de novo use. Nevertheless, the risk of graft loss could be significant in patients with already low renal function.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13544"},"PeriodicalIF":2.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Aspects of Immunogenetics and Post-Transplant Events in Kidney Transplantation. 肾移植中免疫遗传学和移植后事件的新进展。

IF 2.7 3区医学

Transplant International Pub Date : 2024-12-05 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13317

Ilkka Helanterä, Salla Markkinen, Jukka Partanen, Kati Hyvärinen

{"title":"Novel Aspects of Immunogenetics and Post-Transplant Events in Kidney Transplantation.","authors":"Ilkka Helanterä, Salla Markkinen, Jukka Partanen, Kati Hyvärinen","doi":"10.3389/ti.2024.13317","DOIUrl":"10.3389/ti.2024.13317","url":null,"abstract":"HLA typing and matching have been crucial in kidney transplantation, but methods for assessing tissue histocompatibility have advanced significantly. While serological-level HLA typing remains common, it captures only a small fraction of true HLA variation, and molecular matching is already replacing traditional HLA matching. Recent studies have expanded our understanding of genetic tissue compatibility beyond HLA loci. Candidate gene analyses and genome-wide association studies (GWAS) have identified genetic factors linked to post-transplant complications, though replication of these findings is challenging. An alternative approach involves genome-wide matching of genes or genetic variations. This method has shown promise in hematopoietic stem cell and kidney transplantation. For instance, homozygous gene deletions in LIMS1 or complement factor H (CFH) genes have been associated with acute rejection risk. This may be due to alloimmune responses against proteins absent in the patient but present in the graft, or due to the missing protein's function. Genetic studies in clinical medicine face challenges due to the interplay of genetic and environmental factors, necessitating large datasets for meaningful associations. International collaboration and large consortia, like iGeneTRAin, are essential for validating findings and advancing the field. This review highlights recent advancements in immunogenetics and tissue histocompatibility, emphasizing future research directions.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13317"},"PeriodicalIF":2.7,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Genetic Modifications of Source Pigs Are Essential and Sufficient for Cell, Tissue, and Organ Xenotransplantation? 源猪的哪些遗传修饰对于细胞、组织和器官异种移植是必要和充分的？

IF 2.7 3区医学

Transplant International Pub Date : 2024-12-04 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13681

Asghar Ali, Mayuko Kurome, Barbara Kessler, Elisabeth Kemter, Eckhard Wolf

{"title":"What Genetic Modifications of Source Pigs Are Essential and Sufficient for Cell, Tissue, and Organ Xenotransplantation?","authors":"Asghar Ali, Mayuko Kurome, Barbara Kessler, Elisabeth Kemter, Eckhard Wolf","doi":"10.3389/ti.2024.13681","DOIUrl":"10.3389/ti.2024.13681","url":null,"abstract":"Xenotransplantation of porcine organs has made remarkable progress towards clinical application. A key factor has been the generation of genetically multi-modified source pigs for xenotransplants, protected against immune rejection and coagulation dysregulation. While efficient gene editing tools and multi-cistronic expression cassettes facilitate sophisticated and complex genetic modifications with multiple gene knockouts and protective transgenes, an increasing number of independently segregating genetic units complicates the breeding of the source pigs. Therefore, an optimal combination of essential genetic modifications may be preferable to extensive editing of the source pigs. Here, we discuss the prioritization of genetic modifications to achieve long-term survival and function of xenotransplants and summarise the genotypes that have been most successful for xenogeneic heart, kidney, and islet transplantation. Specific emphasis is given to the choice of the breed/genetic background of the source pigs. Moreover, multimodal deep phenotyping of porcine organs after xenotransplantation into human decedents will be discussed as a strategy for selecting essential genetic modifications of the source pigs. In addition to germ-line gene editing, some of these modifications may also be induced during organ preservation/perfusion, as demonstrated recently by the successful knockdown of swine leukocyte antigens in porcine lungs during ex vivo perfusion.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13681"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can We Noninvasively Rule Out Acute Rejection? External Validation of a Urinary Chemokine-Based Model. 我们能否无创排除急性排斥反应？基于尿液趋化因子模型的外部验证。

IF 2.7 3区医学

Transplant International Pub Date : 2024-12-04 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13810

Ilaria Gandolfini, Benedetta Mordà, Elena Martinelli, Marco Delsante, Giovanni Maria Rossi, Micaela Gentile, Sara Alibrandi, Daniel Salvetti, Omar Ben Youssif, Enrico Fiaccadori, Alessandra Palmisano, Paolo Cravedi, Umberto Maggiore

引用次数: 0

Donor-Specific Antibodies Targeting a Repeated Eplet Mismatch and Outcome After Kidney Retransplantation. 针对重复Eplet错配的供体特异性抗体和肾再移植后的结果。

IF 2.7 3区医学

Transplant International Pub Date : 2024-11-29 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13639

Caroline Arches, Cédric Usureau, Dany Anglicheau, Alexandre Hertig, Arwa Jalal-Eddine, Mohamad Zaidan, Jean-Luc Taupin, Renaud Snanoudj

{"title":"Donor-Specific Antibodies Targeting a Repeated Eplet Mismatch and Outcome After Kidney Retransplantation.","authors":"Caroline Arches, Cédric Usureau, Dany Anglicheau, Alexandre Hertig, Arwa Jalal-Eddine, Mohamad Zaidan, Jean-Luc Taupin, Renaud Snanoudj","doi":"10.3389/ti.2024.13639","DOIUrl":"10.3389/ti.2024.13639","url":null,"abstract":"Kidney retransplantations are associated with an increased risk of rejection and reduced graft survival compared to first transplantations, notably due to HLA sensitization. The impact of repeated eplet mismatches on retransplantation outcome has not been investigated. We retrospectively assessed the risk of antibody-mediated rejection (ABMR) and graft loss associated with preformed DSA targeting Repeated Eplet MisMatches (DREMM) in sensitized patients undergoing kidney retransplantation. We included 45 retransplanted patients with preformed DSA against the second donor. We determined HLA incompatibilities at the eplet levels, and the eplet target of the DSA using HLAMatchmaker®. Repeated mismatches were more frequent at the eplet (87%) than at the antigenic level (22%), but were not associated with the risk of ABMR. The eplet specificity of the DSA revealed that 60% of patients (n = 27) had DREMM. The presence of DREMM was associated with a higher frequency of ABMR (70% versus 28%, P = 0.005) and with a lower death-censored graft survival (log-rank test, P = 0.01). However, in multivariate Cox model, we could not show that DREMM were associated with the risk of ABMR. In conclusion, this study suggests that identifying DREMM may be an interesting clinical tool, however further larger studies are necessary to precise their exact predictive value.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13639"},"PeriodicalIF":2.7,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11637850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transplant Trial Watch. 移植试验观察。

IF 2.7 3区医学

Transplant International Pub Date : 2024-11-28 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.14062

John M O'Callaghan, Simon R Knight, Reshma Rana Magar

引用次数: 0

Shedding Light on Microvascular Inflammation: Understanding Outcomes, But What Sparks the Flame? 揭示微血管炎症：了解结果，但是什么点燃了火焰？

IF 2.7 3区医学

Transplant International Pub Date : 2024-11-26 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.14032

Louise Benning, Oriol Bestard

引用次数: 0

Opinions on the Future of Clinical Pig Kidney Xenotransplantation. 对临床猪肾异种移植的展望。

IF 2.7 3区医学

Transplant International Pub Date : 2024-11-26 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13475

Georg A Böhmig, Matthias Diebold, Klemens Budde

{"title":"Opinions on the Future of Clinical Pig Kidney Xenotransplantation.","authors":"Georg A Böhmig, Matthias Diebold, Klemens Budde","doi":"10.3389/ti.2024.13475","DOIUrl":"10.3389/ti.2024.13475","url":null,"abstract":"Based on promising results obtained in primate models, pioneers in the US have now started to explore the new frontier of genetically-edited pig-to-human transplantation. The recent transition of xenotransplantation into clinical medicine has included transplants in brain-dead subjects and the compassionate use of xenotransplants in living recipients without options for allotransplantation. While the barrier of hyperacute rejection seems to be successfully overcome by gene editing of donor pigs, the occurrence of accelerated rejection could pose significant limitations to the success of the procedure. Ultimately, the establishment of efficient and safe strategies to overcome immunologic barriers will, among other critical factors, such as potential xenozoonotic disease transmission or physiological differences, determine whether and for which indications xenotransplantation will be viable. Considering preliminary outcomes of compassionate use xenotransplantions, which may raise questions about how faithfully data from non-human primate models translate into human outcomes, further research in decedents may be necessary before proceeding with additional clinical transplants. Looking ahead, designing systematic trials in xenotransplantation, including the definition of acceptable eligibility criteria for such high-risk transplants, will be an immense challenge, especially in kidney transplantation, where dialysis provides an effective alternative to transplantation in most cases.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13475"},"PeriodicalIF":2.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits. 肾移植患者的癌症免疫治疗：风险与收益之间的艰难平衡。

IF 2.7 3区医学

Transplant International Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13204

Mónica Bolufer, Jordi Soler, María Molina, Omar Taco, Anna Vila, Manuel Macía

{"title":"Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.","authors":"Mónica Bolufer, Jordi Soler, María Molina, Omar Taco, Anna Vila, Manuel Macía","doi":"10.3389/ti.2024.13204","DOIUrl":"10.3389/ti.2024.13204","url":null,"abstract":"Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to maintain the patient in a delicate immunologic balance in which, while antitumor therapy defeats cancer the graft is safely protected from rejection. Recent clinical trials with ICPI have included kidney transplant recipients (KTRs) and the results advocate for a paradigm shift in the management of basal immunosuppression. This suggests that downward adjustments should be avoided or, even better, that this adjustment should be \"dynamic.\" This review summarizes the latest scientific evidence available in renal transplantation under ICPI treatment: case series, prospective studies, histopathologic diagnosis, immunosuppression regimens and new biomarkers. This article will provide the latest information in on this specific field, allowing nephrologists to gain valuable knowledge and to be aware of new approaches to immunosuppression management in oncological kidney transplant patients.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13204"},"PeriodicalIF":2.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0